Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial - Summary - MDSpire

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial

  • By

  • Hiroshi Ureshino

  • Kazunori Murai

  • Takashi Kumagai

  • Tatsuji Mino

  • Kaichi Nishiwaki

  • Satoshi Wakita

  • Tomoharu Takeoka

  • Masayuki Mita

  • Chikashi Yoshida

  • Nobuhiko Uoshima

  • Toshihiro Fukushima

  • Junya Kuroda

  • Takeshi Kondo

  • Masahiro Chiba

  • Takuya Miyazaki

  • Katsuhiro Io

  • Tomoaki Ueda

  • Takaaki Ono

  • Kensuke Usuki

  • Takahiro Yamauchi

  • Katsumichi Fujimaki

  • Takayuki Ikezoe

  • Atsushi Kawaguchi

  • Shinya Kimura

  • May 28, 2026

  • 0 min

Share

Objective:

To evaluate the long-term efficacy and safety of low-dose dasatinib in elderly patients with chronic phase chronic myeloid leukemia (CML-CP), highlighting the significance of this treatment in a vulnerable population, using extended follow-up data from the DAVLEC cohort.

Key Findings:
  • 5-year cumulative incidence rates: MMR 89.3%, MR4.0 69.6%, MR4.5 56.7%.
  • At 12 months, 56.3% of patients achieved MMR.
  • Early molecular response (EMR) significantly increased likelihood of achieving MMR.
  • 25% of patients experienced grade ≥3 AEs, with cardiovascular AEs being the most common, impacting treatment decisions.
  • 5-year OS rate was 85.5%, with most deaths due to heart failure or other cancers.
Interpretation:

The study suggests that low-dose dasatinib is effective and has a manageable safety profile in elderly patients with CML-CP, indicating potential for improved clinical outcomes.

Limitations:
  • The study was conducted at 25 hospitals in Japan, which may limit generalizability.
  • The observational nature of long-term follow-up may introduce biases, potentially affecting the reliability of the findings.
Conclusion:

Low-dose dasatinib appears to provide a favorable balance between efficacy and tolerability in elderly CML-CP patients over the long term, underscoring the need for continued long-term follow-up in this population.

Original Source(s)

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial

  • by Hiroshi Ureshino, Kazunori Murai, Takashi Kumagai, Tatsuji Mino, Kaichi Nishiwaki, Satoshi Wakita, Tomoharu Takeoka, Masayuki Mita, Chikashi Yoshida, Nobuhiko Uoshima, Toshihiro Fukushima, Junya Kuroda, Takeshi Kondo, Masahiro Chiba, Takuya Miyazaki, Katsuhiro Io, Tomoaki Ueda, Takaaki Ono, Kensuke Usuki, Takahiro Yamauchi, Katsumichi Fujimaki, Takayuki Ikezoe, Atsushi Kawaguchi, Shinya Kimura

  • May 28, 2026

Related Content

Severe immune checkpoint inhibitor-induced 3M syndrome: a case report

CD38+ NK cells: novel players in immunoregulation

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review